Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients

A. Veronesi, D. Crivellari, M. D. Magri, G. Cartel, M. Mansutti, S. Foladore, S. Monfardini

Research output: Contribution to journalArticle

Abstract

The aim of this study was to investigate the activity and the toxicity of vinorelbine (VNB) in a population of patients with locally advanced inoperable or metastatic non-small cell lung cancer (NSCLC) including elderly patients unfit for cisplatin-based chemotherapy. VNB was administered at a dose of 25-30 mg/m2, intravenously, weekly until progression. Of the 83 patients who entered the study (median age 63 years, number of patients aged 3=70 years = 23, median performance status = SO, stage IV in 58 patients, previous chemotherapy in 15 patients), 76 were évaluable. One complete remission and 22 partial remissions were noted (30.2% réponse rate). Toxicity was mild. Median survival was 9 months. No effect of age upon outcome was detected. Thus, single agent VNB is a reasonable option for advanced NSCLC, particularly in elderly patients.

Original languageEnglish
Pages (from-to)1803-1808
Number of pages6
JournalEuropean Journal of Cancer
Volume32
Issue number10
Publication statusPublished - 1996

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Drug Therapy
vinorelbine
Cisplatin
Survival
Population

Keywords

  • Elderly patients
  • Non-small cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Veronesi, A., Crivellari, D., Magri, M. D., Cartel, G., Mansutti, M., Foladore, S., & Monfardini, S. (1996). Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. European Journal of Cancer, 32(10), 1803-1808.

Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. / Veronesi, A.; Crivellari, D.; Magri, M. D.; Cartel, G.; Mansutti, M.; Foladore, S.; Monfardini, S.

In: European Journal of Cancer, Vol. 32, No. 10, 1996, p. 1803-1808.

Research output: Contribution to journalArticle

Veronesi, A, Crivellari, D, Magri, MD, Cartel, G, Mansutti, M, Foladore, S & Monfardini, S 1996, 'Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients', European Journal of Cancer, vol. 32, no. 10, pp. 1803-1808.
Veronesi A, Crivellari D, Magri MD, Cartel G, Mansutti M, Foladore S et al. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. European Journal of Cancer. 1996;32(10):1803-1808.
Veronesi, A. ; Crivellari, D. ; Magri, M. D. ; Cartel, G. ; Mansutti, M. ; Foladore, S. ; Monfardini, S. / Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. In: European Journal of Cancer. 1996 ; Vol. 32, No. 10. pp. 1803-1808.
@article{beaa413825cd49b684c66f177a5d87d4,
title = "Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients",
abstract = "The aim of this study was to investigate the activity and the toxicity of vinorelbine (VNB) in a population of patients with locally advanced inoperable or metastatic non-small cell lung cancer (NSCLC) including elderly patients unfit for cisplatin-based chemotherapy. VNB was administered at a dose of 25-30 mg/m2, intravenously, weekly until progression. Of the 83 patients who entered the study (median age 63 years, number of patients aged 3=70 years = 23, median performance status = SO, stage IV in 58 patients, previous chemotherapy in 15 patients), 76 were {\'e}valuable. One complete remission and 22 partial remissions were noted (30.2{\%} r{\'e}ponse rate). Toxicity was mild. Median survival was 9 months. No effect of age upon outcome was detected. Thus, single agent VNB is a reasonable option for advanced NSCLC, particularly in elderly patients.",
keywords = "Elderly patients, Non-small cell lung cancer, Vinorelbine",
author = "A. Veronesi and D. Crivellari and Magri, {M. D.} and G. Cartel and M. Mansutti and S. Foladore and S. Monfardini",
year = "1996",
language = "English",
volume = "32",
pages = "1803--1808",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients

AU - Veronesi, A.

AU - Crivellari, D.

AU - Magri, M. D.

AU - Cartel, G.

AU - Mansutti, M.

AU - Foladore, S.

AU - Monfardini, S.

PY - 1996

Y1 - 1996

N2 - The aim of this study was to investigate the activity and the toxicity of vinorelbine (VNB) in a population of patients with locally advanced inoperable or metastatic non-small cell lung cancer (NSCLC) including elderly patients unfit for cisplatin-based chemotherapy. VNB was administered at a dose of 25-30 mg/m2, intravenously, weekly until progression. Of the 83 patients who entered the study (median age 63 years, number of patients aged 3=70 years = 23, median performance status = SO, stage IV in 58 patients, previous chemotherapy in 15 patients), 76 were évaluable. One complete remission and 22 partial remissions were noted (30.2% réponse rate). Toxicity was mild. Median survival was 9 months. No effect of age upon outcome was detected. Thus, single agent VNB is a reasonable option for advanced NSCLC, particularly in elderly patients.

AB - The aim of this study was to investigate the activity and the toxicity of vinorelbine (VNB) in a population of patients with locally advanced inoperable or metastatic non-small cell lung cancer (NSCLC) including elderly patients unfit for cisplatin-based chemotherapy. VNB was administered at a dose of 25-30 mg/m2, intravenously, weekly until progression. Of the 83 patients who entered the study (median age 63 years, number of patients aged 3=70 years = 23, median performance status = SO, stage IV in 58 patients, previous chemotherapy in 15 patients), 76 were évaluable. One complete remission and 22 partial remissions were noted (30.2% réponse rate). Toxicity was mild. Median survival was 9 months. No effect of age upon outcome was detected. Thus, single agent VNB is a reasonable option for advanced NSCLC, particularly in elderly patients.

KW - Elderly patients

KW - Non-small cell lung cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=33748459096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748459096&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 1803

EP - 1808

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -